Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human DLC1 Anticorps:
anti-Mouse (Murine) DLC1 Anticorps:
anti-Rat (Rattus) DLC1 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal DLC1 Primary Antibody pour IHC (p), IHC - ABIN268701
Ko, Yeung, Wong, Chan, Poon, Ng, Yam: Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma. dans Liver international : official journal of the International Association for the Study of the Liver 2009
Show all 2 Pubmed References
Human Polyclonal DLC1 Primary Antibody pour IHC (p), ELISA - ABIN547321
Wilson, McGlinn, Marsh, Evans, Arnold, Wright, Biden, Young, Wainwright, Wicking, Chenevix-Trench: Sequence variants of DLC1 in colorectal and ovarian tumours. dans Human mutation 2000
Human Polyclonal DLC1 Primary Antibody pour IHC, IHC (p) - ABIN4305321
Muehlich, Hampl, Khalid, Singer, Frank, Breuhahn, Gudermann, Prywes: The transcriptional coactivators megakaryoblastic leukemia 1/2 mediate the effects of loss of the tumor suppressor deleted in liver cancer 1. dans Oncogene 2012
Findings imply that loss of deleted in liver cancer 1 (DLC1) contributes to the progression and oncogenic autophagy of hepatocellular carcinoma (HCC).
findings reveal that DLC1 maintains basal activation of PKD at the Golgi and Golgi secretory activity, in part by down-regulating Rho-ROCK signaling
Phosphoproteomics analysis documented an inverse relation between DLC1 expression and several phosphopeptides including epithelial cell transforming sequence 2 (ECT2).
Low DLC1 expression is associated with Angiosarcoma.
DLC1 is the predominant family member expressed in several normal tissues, and its expression is preferentially reduced in common cancers at these sites.
Fluctuation of reactive oxygen species inhibited migration through reducing the interaction between DLC1 and CAV-1.
IGF2 may exert its oncofunction, at least partly, through its parasitic miR-483 which suppressed DLC-1 in colorectal cancer cells. DLC-1 expression was decreased in colorectal cancer tissues and diminished through transient transfection with miR-483-3p.
The results of this study showed for the first time that CpGs of the DLC1-v1 alternative promoter is frequently hypermethylated in tumors of meningeal origin.
Receptor tyrosine kinase activation of RhoA is mediated by AKT phosphorylation of DLC1.
Study suggests a mechanism for EZH2-H3K27me3 epigenetic repression of DLC1 and multilayered regulation of DLC1/Rho/ROCK signaling by EZH2, and advocated the significant pro-metastatic role of EZH2 via repressing tumor and metastasis suppressors.
The results identify DLC1 as an activator of white and brown adipocyte differentiation, and provide a molecular link between PPARgamma and Rho pathways.
DLC-1 has a positive regulatory role in endothelial cell angiogenesis.
Subsequent studies have demonstrated that DLC-1 is generally expressed in normal human tissues as well as in rats, while it always exists inactivated or even lost in many human cancers, which characterizes DLC-1 as a potential tumor suppressor. [review]
Tumor suppressor genes deleted in liver cancer 1 (DLC1), F-box/WD-repeat-containing protein 7 (FBXW7), and cadherin-6 (CDH6) were identified as presumed targets in Cholangiocarcinoma (CC).Inverse correlation between promoter methylation and expression suggested miR-129-2 and members of the miR-200 family (miR-200a, miR-200b, and miR-429) as novel tumor suppressors and oncomiRs, respectively, in CC
it was demonstrated that the rs621554 polymorphism was correlated with DLC1 expression at the mRNA level. These results suggested that the rs621554 polymorphism is associated with breast cancer susceptibility and prognosis, and may serve as a biomarker for breast cancer development and progression.
curcumin down-regulates the expression of Sp1 to inhibit the expression of DNA methyltransferase 1, thus subsequently reducing hypermethylation of DLC1 promoter to induce DLC1 expression.
DLC-1 acts as a tumor suppressor gene in HCC by regulating the expression of RhoA/ROCK2/ moesin.
Low DLC-1 expression is associated with cancer.
Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer.
No significant association of DLC1 SNPs with the patients' prognosis was found.
talin unfolding determines DLC1 downstream signalling and, consequently, cell mechanics.
studies demonstrate that TNS1 binds to DLC1 and fine-tunes its RhoGAP activity toward RhoA and that the TNS1-DLC1-RhoA signaling axis is critical in regulating cellular functions that lead to angiogenesis
Loss of expression of only Dlc1 isoform 2 may be sufficient for the development of thymic tumors and metastasis.
Several genes and biochemical activities collaborate with the inactivation of DLC1 to give rise to cell transformation in MEFs, and the identified genes are relevant to human tumors with low DLC1 expression.
The Dlc1 deficient cells showed altered cytoskeleton structure, increased RhoA activity and cellular migration.
DLC-1-/- embryos had defects in the neural tube, brain, heart, and placenta
Our data validate DLC1 as a potent tumor suppressor gene and suggest that its loss creates a dependence on the RhoA pathway that may be targeted therapeutically.
This gene encodes a GTPase-activating protein (GAP) that is a member of the rhoGAP family of proteins which play a role in the regulation of small GTP-binding proteins. GAP family proteins participate in signaling pathways that regulate cell processes involved in cytoskeletal changes. This gene functions as a tumor suppressor gene in a number of common cancers, including prostate, lung, colorectal, and breast cancers. Multiple transcript variants due to alternative promoters and alternative splicing have been found for this gene.
Rho-GTPase-activating protein 7
, START domain-containing protein 12
, StAR-related lipid transfer (START) domain containing 12
, deleted in liver cancer 1 protein
, deleted in liver cancer 1 variant 2
, rho GTPase-activating protein 7
, rho-type GTPase-activating protein 7
, deleted in liver cancer 1
, deleted in liver cancer 1 protein homolog
, stAR-related lipid transfer protein 12
, rho GTPase-activating protein 7-like
, Deleted in liver cancer 1 protein homolog
, Rho-type GTPase-activating protein 7
, rho GTPase activating protein 7